ECSP003706A - Compuestos farmaceuticamente activos - Google Patents

Compuestos farmaceuticamente activos

Info

Publication number
ECSP003706A
ECSP003706A ECSP003706A ECSP003706A EC SP003706 A ECSP003706 A EC SP003706A EC SP003706 A ECSP003706 A EC SP003706A EC SP003706 A ECSP003706 A EC SP003706A
Authority
EC
Ecuador
Prior art keywords
active compounds
pharmaceutically active
given
compounds
guanosine
Prior art date
Application number
Other languages
English (en)
Inventor
Charlotte Moira Norfor Allerton
David James Rawson
Christopher Gordon Barber
Graham Nigel Maw
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP003706A publication Critical patent/ECSP003706A/es

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan compuestos de fórmula I: en la que R1, R2, R3, R4 y X tienen los significados dados en la memoria descriptiva, los cuales son útiles para el tratamiento curativo y profiláctico de un trastorno médico para el que se de sea la inhibición de una guanosín 35´´-monofosfato cíclico fosfodiesterasa (po ejemplo cGMP PDE5).
ECSP003706 1999-10-11 2000-10-10 Compuestos farmaceuticamente activos ECSP003706A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924041.8A GB9924041D0 (en) 1999-10-11 1999-10-11 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
ECSP003706A true ECSP003706A (es) 2002-05-23

Family

ID=10862532

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP003706 ECSP003706A (es) 1999-10-11 2000-10-10 Compuestos farmaceuticamente activos

Country Status (3)

Country Link
EC (1) ECSP003706A (es)
GB (1) GB9924041D0 (es)
ZA (1) ZA200202723B (es)

Also Published As

Publication number Publication date
GB9924041D0 (en) 1999-12-15
ZA200202723B (en) 2003-04-08

Similar Documents

Publication Publication Date Title
UY26383A1 (es) "compuestos farmacéuticamente activos"
BR0004779A (pt) Compostos farmaceuticamente ativos
PT1123296E (pt) Inibidores de cgmp pdes derivados da pirazolopirimidinona para tratamento da disfuncao sexual
ATE283856T1 (de) Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
ATE298753T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung der sexuellen dysfunktion
CA2287552A1 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
CA2322900A1 (en) 2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
NO20052927L (no) 2,4,6-trisubstituerte pyrimidiner av fosfotidylinositol (PI) 3-kinaseinhibitorer og deres anvendelse ved behandling av kreft
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
ATE298238T1 (de) Pyrazolo(4,3-d)pyrimidinon-verbindungen als cgmp pde-inhibitoren
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
DE60130023D1 (de) Behandlung der nebenwirkungen von statinen
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
TR200200989T2 (tr) Farmasötik açıdan aktif bileşikler.
CY1105390T1 (el) Θepαπευτικη αγωγη της πνευμονικης υπερτασης
SE9701304D0 (sv) Compounds
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
BR0208463A (pt) Compostos farmaceuticamente ativos
ECSP003706A (es) Compuestos farmaceuticamente activos
YU6396A (sh) Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija
SE9701396D0 (sv) Compounds
AR024393A1 (es) Nuevos compuestos de bispidina para usar en el tratamiento de las arritmias cardiacas.
DK0814813T3 (da) Anvendelse af penciclovir til behandling af human herpesvirus-8